Duraibabu Prathyusha bought SGMO

January 22, 2024 · Form 4 insider transaction

Duraibabu Prathyusha bought 712,500 shares of Sangamo Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Acquired (buy-side)
Shares
712,500
Price
$0.00
Total value
N/A
RoleOfficer
SecurityCommon Stock
Transaction codeA: Grant or award
Transaction dateJanuary 22, 2024
Filing dateJanuary 24, 2024
Shares owned after843,505
OwnershipDirect
10b5-1 planNo
AmendedNo

Footnotes

Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration in full in the event of a Change in Control (as defined in the 2018 EIP).; Includes: (a) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (b) 19,219 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 53,438 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter and (d) 2,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in one final installment on June 11, 2024. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

View the original Form 4 on SEC EDGAR